临床输血与检验 ›› 2026, Vol. 28 ›› Issue (5): 882-894.DOI: 10.3969/j.issn.1671-2587.2026.05.028
• 综述 • 上一篇
陈甜甜1, 邱进2, 李菲2, 陈伟2
收稿日期:2026-09-03
修回日期:2026-09-18
出版日期:2026-10-20
发布日期:2026-11-11
通讯作者:
陈伟,主要从事输血医学与免疫血液学研究,(E-mail)29286889@qq.com。
作者简介:陈甜甜,主要从事输血医学与免疫血液学研究,(E-mail)1084113253@qq.com。
基金资助:CHEN Tiantian1, QIU Jin2, LI Fei2, CHEN Wei2
Received:2026-09-03
Revised:2026-09-18
Online:2026-10-20
Published:2026-11-11
摘要: 肝素诱导的血小板减少症(HIT)是肝素类药物引起的严重免疫不良反应,主要由抗血小板因子4(PF4)-肝素复合物IgG抗体介导,以血小板计数进行性下降及血栓形成风险增加为特征。临床上HIT主要分为Ⅰ型和Ⅱ型两种,其中Ⅱ型危害较大,若未及时诊治,严重时可导致患者残疾甚至死亡。目前临床多采用4Ts评分结合实验室检查进行诊断,其中免疫筛查试验的检测灵敏度高但特异性较差。5-羟色胺释放试验(SRA)是目前公认的功能学金标准(灵敏度90%~95%,特异性>98%)。近年来,随着检验技术的不断发展,自动化化学发光免疫检测、新型快速功能试验、流式细胞技术等新技术的逐步应用,优化了HIT的诊断流程。本文系统梳理了HIT的发病特点、临床分型及典型症状,对比各类HIT实验室检测方式的利弊点及最新研究进展,以期能为临床快速识别HIT、精准开展检验工作提供一定的参考。
中图分类号:
陈甜甜, 邱进, 李菲, 陈伟. 肝素诱导的血小板减少症临床特点及实验室检测研究进展*[J]. 临床输血与检验, 2026, 28(5): 882-894.
CHEN Tiantian, QIU Jin, LI Fei, CHEN Wei. Heparin-Induced Thrombocytopenia: Clinical Characteristics and Research Progress in Laboratory Diagnostics[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(5): 882-894.
| [1] 何武剑,沈莉,洪旭林,等. 肝素诱导的血小板减少症的发病机制及治疗进展[J]. 中华内科杂志,2024,63(11):1128-1136. [2] 闫姝洁,卞璐瑜,滕媛,等. 肝素诱导血小板减少症成人体外循环管理临时专家共识[J]. 中国体外循环杂志,2024, 22(2):82-86. [3] Greinacher A.Heparin-induced thrombocytopenia[J]. N Engl J Med,2015,373(19):1883-1884. [4] Anthon C T,Pène F,Perner A,et al.Thrombocytopenia and platelet transfusions in ICU patients: an international inception cohort study (PLOT-ICU)[J]. Intensive Care Med,2023,49(11):1327-1338. [5] 陈梓欣,周洲,张洋. 肝素诱导的血小板减少症实验室检测新进展[J]. 中华检验医学杂志,2025,48(8):1095-1100. [6] 汪玲玲,程刚,奂剑波. 我国肝素诱导的血小板减少症的文献计量学分析[J]. 沈阳药科大学学报,2022,39(6):717-724. [7] Warkentin T E,Greinacher A.Platelet-activating anti-platelet factor 4 disorders[J]. N Engl J Med,2026,395(5): 478-491. [8] 周洋,谢旻. 凝血收敛模型下肝素和疫苗诱导血小板减少症的发病机制与临床特征[J]. 实用医学杂志,2025, 41(18):2828-2838. [9] Treverton J,Arnold D M,Ivanov D G,et al.Monoclonal antibodies in the pathogenesis of heparin-induced thrombocytopenia[J]. N Engl J Med,2025,393(9):879-886. [10] Ma Q L,Huang J F,Mak E,et al.A cryptic symmetry switch allosterically controls how the PF4 self-protein turns into a pathogenic antigen[J]. Nat Commun,2026, 17:9352. [11] Myoung S S,Francis S J,Chen J,et al.Complement activation as a biomarker for platelet-activating antibodies in heparin-induced thrombocytopenia[J]. J Thromb Haemost,2025,23(3):1066-1076. [12] Ahmed I,Majeed A,Powell R.Heparin induced thrombocytopenia: diagnosis and management update[J]. Postgrad Med J,2007,83(983):575-582. [13] Arepally G M,Ortel T L.Heparin-induced thrombocytopenia[J]. N Engl J Med,2006,355(8):809-817. [14] 中国医师协会心血管内科医师分会血栓防治专业委员会,韩雅玲,许俊堂,等. 肝素诱导的血小板减少症中国专家共识(2017)[J]. 中华医学杂志,2018,98(6):408-417. [15] 许俊堂. 肝素诱导的血小板减少症中国专家共识解读[J]. 中国循环杂志,2018,33(S2):117-120. [16] 韩冰,王岩,杜佳欣,等. 肝素诱导的血小板减少症42例临床特征分析[J]. 中国实用医刊,2023,50(16):5-8. [17] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 非ST段抬高型急性冠脉综合征诊断和治疗指南(2024)[J]. 中华心血管病杂志,2024,52(6):615-646. [18] Dutt T,Schulz M.Heparin-induced thrombocytopaenia (HIT)—an overview: what does the nephrologist need to know and do?[J]. Clin Kidney J,2013,6(6):563-567. [19] Warkentin T E,Kelton J G.A 14-year study of heparin-induced thrombocytopenia[J]. Am J Med,1996,101(5): 502-507. [20] Warkentin T E,Levine M N,Hirsh J,et al.Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin[J]. N Engl J Med,1995,332(20):1330-1336. [21] Warkentin T E,Cook R J,Marder V J,et al.Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin[J]. Blood,2005,106(12):3791-3796. [22] Yu M,Zhou L,Zhang Y G,et al.Jmjd1c-mediated epigenetic control of autoimmunity and HIT antibody production[J]. Blood,2026,148(9):1175-1190. [23] Lubenow N,Hinz P,Thomaschewski S,et al.The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia[J]. Blood,2010,115(9):1797-1803. [24] Warkentin T E,Sheppard J A,Sigouin C S,et al.Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia[J]. Blood,2006,108(9):2937-2941. [25] Warkentin T E,Kelton J G.Temporal aspects of heparin-induced thrombocytopenia[J]. N Engl J Med,2001, 344(17):1286-1292. [26] Capuano I,Riccio E,Buonanno P,et al. Heparin-induced thrombocytopenia: a challenging diagnosis in haemodialysis—state of art and review of the literature[J]. Clin Kidney J,2026,19(4):sfag062. [27] 侯为洁,王春燕,洪涛,等. 肝素诱导的血小板减少症所致的冠状动脉血栓形成1例[J]. 中华心血管病杂志,2025, 53(6):682-684. [28] Marini I,Uzun G,Jamal K,et al.Treatment of drug-induced immune thrombocytopenias[J]. Haematologica, 2022,107(6):1264-1277. [29] Nicolaides A,Fareed J,Kakkar A K,et al.Prevention and treatment of venous thromboembolism: international consensus statement (guidelines according to scientific evidence)[J]. Clin Appl Thromb Hemost,2013,19(2): 116-118. [30] Gruel Y,Vayne C,Rollin J,et al.Comparative analysis of a French prospective series of 144 patients with heparin-induced thrombocytopenia (FRIGTIH) and the literature[J]. Thromb Haemost,2020,120(7):1096-1107. [31] Arepally G M,Padmanabhan A.Heparin-induced thrombocytopenia: a focus on thrombosis[J]. Arterioscler Thromb Vasc Biol,2021,41(1):141-152. [32] Nepal N,Patel D,Omosebi O,et al.Type II heparin-induced thrombocytopenia manifesting as cardiac arrest following intravenous heparin bolus during an elective procedure: a case report and literature review[J]. Cureus, 2024,16(3):e57072. [33] Warkentin T E.Autoimmune heparin-induced thrombocytopenia[J]. J Clin Med,2023,12(21):6921. [34] Chatterjee S,Girardi N I,Crow J,et al.2026 American Association for Thoracic Surgery Expert Consensus Document: Diagnosis and management of heparin-induced thrombocytopenia in patients who undergo cardiac surgery[J]. J Thorac Cardiovasc Surg,2026,172(3):487-509.e3. [35] Warkentin T E,Greinacher A,Gruel Y,et al.Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis[J]. J Thromb Haemost,2011,9(12):2498-2500. [36] Billy S,Vayne C,Bertin O,et al.Cooperative effect between anti-PF4/H and anti-PF4 antibodies increases cell activation and thrombotic risk in HIT[J]. Blood Adv,2025,9(12):3106-3115. [37] Nagler M,Bakchoul T.Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia[J]. Thromb Haemost,2016,116(11):823-834. [38] Larsen E L,Nilius H,Studt J D,et al.Accuracy of diagnosing heparin-induced thrombocytopenia[J]. JAMA Netw Open,2024,7(3):e243786. [39] Ampatzidou F,Argyriadou E,Amaniti C,et al.Postoperative thrombocytopenia in cardiac surgery: patterns,differential diagnosis and management of heparin-induced thrombocytopenia (HIT)[J]. JCM,2025, 14(24):8765. [40] Koster A,Nagler M,Erdoes G,et al.Heparin-induced thrombocytopenia: perioperative diagnosis and management[J]. Anesthesiology,2022,136(2):336-344. [41] Cuker A,Gimotty P A,Crowther M A,et al.Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis[J]. Blood,2012,120(20):4160-4167. [42] Arachchillage D J,Thachil J,Anderson J A M,et al. Diagnosis and management of heparin-induced thrombocytopenia: Third edition[J]. Br J Haematol,2024, 204(2):459-475. [43] Husseinzadeh H D,Gimotty P A,Pishko A M,et al.Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparin-induced thrombocytopenia: a systematic review and meta-analysis[J]. J Thromb Haemost,2017,15(6):1203-1212. [44] Maličev E,Urbajs M,Gradišar K J,et al. Dilution-endpoint comparison of a flow cytometric platelet activation assay with PF4/heparin ELISA and a lateral flow immunoassay in suspected HIT[J]. Int J Lab Hematology,2026:ijlh.70210. [45] 任静,李刚,门剑龙. 肝素诱导的血小板减少症抗体试验的诊断性能评价[J]. 临床检验杂志,2017,35(12):921-924. [46] Zhou L,Cao A,Zhu W,et al.Non-PF4/heparin-binding,platelet-activating antibodies in heparin-induced thrombocytopenia[J]. Blood,2026,148(1):115-129. [47] Steinauer T,Matthey-Guirao E,Gomez F J,et al.Sequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopenia[J]. Blood,2025,146(7):887-896. [48] Langer A L,Vest L S,Connors J M,et al.Spontaneous heparin-induced thrombocytopenia after total hip arthroplasty[J]. N Engl J Med,2026,394(6):612-614. [49] Sachs U J,von Hesberg J,Santoso S,et al. Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT)[J]. Thromb Haemost,2011,106(6):1197-1202. [50] Favaloro E J.Laboratory tests for identification or exclusion of heparin induced thrombocytopenia: HIT or miss?[J]. American J Hematol,2018,93(2):308-314. [51] 李森,范连凯,吴为,等. 二种检测肝素/PF4复合物抗体免疫学方法在肝素诱导的血小板减少症中的诊断价值[J]. 中华血液学杂志,2019,40(5):411-416. [52] Sun L,Gimotty P A,Lakshmanan S,et al.Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia: A systematic review and meta-analysis[J]. Thromb Haemost,2016,115(5):1044-1055. [53] Cobbaert C,Neumaier M,Capoluongo E,et al.EFLM position statement on the proposed 2025/0404(COD) IVDR Amendment of Article 5.5[J]. Clin Chem Lab Med CCLM,2026,64(7):1455-1466. [54] 中国研究型医院学会血栓与止血专委会,中国老年医学学会检验分会,周洲,等. 肝素类药物临床监测专家共识[J]. 中华检验医学杂志,2025,48(8):962-978. [55] Tardy B,Lecompte T,Mullier F,et al.Detection of platelet-activating antibodies associated with heparin-induced thrombocytopenia[J]. J Clin Med,2020,9(4):1226. [56] Padmanabhan A,Jones C G,Curtis B R,et al.A novel PF4-dependent platelet activation assay identifies patients likely to have heparin-induced thrombocytopenia/thrombosis[J]. Chest,2016,150(3):506-515. [57] Pelzl L,Uzun G,Marini I,et al.Heparin-activated procoagulant platelet assay: a flow cytometry-based functional test for heparin-induced thrombocytopenia[J]. J Thromb Haemost,2024,22(2):470-479. [58] Carré J,Demont Y,Mouton C,et al.Imaging flow cytometry as a novel approach for the diagnosis of heparin-induced thrombocytopenia[J]. Br J Haematol, 2025,206(2):666-674. [59] Rial C,Gendron N,Le Beller C,et al.Evaluation of an IgG anti-PF4/H chemiluminescent immunoassay in the diagnosis of heparin-induced thrombocytopenia[J]. Blood Vessel Thromb Hemost,2025,2(4):100084. [60] Herb A,Depierreux M,Wimmer J,et al.Laboratory diagnosis of heparin-induced thrombocytopenia: A retrospective experience[J]. J Clin Lab Anal,2023,37(7): e24884. [61] Warkentin T E,Smythe M A,Ali M A,et al.Serotonin-release assay-positive but platelet factor 4-dependent enzyme-immunoassay negative: HIT or not HIT?[J]. American J Hematol,2021,96(3):320-329. [62] Pouplard C,Charuel N,Archer E,et al.Evaluation of 5B9 as a calibrator or expression of results in absorbance values for the diagnosis of hit with a PF4/heparin specific elisa[J]. Int J Lab Hematology,2026,48(1):165-171. [63] Yates S G,Webb C B,Scheid L M,et al.Performance evaluation of a reflexive algorithm for suspected heparin-induced thrombocytopenia[J]. Res Pract Thromb Haemost,2026,10(5):106866. [64] Warkentin T E,Sheppard J I,Smith J W,et al.Combination of two complementary automated rapid assays for diagnosis of heparin-induced thrombocytopenia (HIT)[J]. J Thromb Haemost,2020,18(6):1435-1446. [65] Favaloro E J,Mohammed S,Donikian D,et al.A multicentre assessment of contemporary laboratory assays for heparin induced thrombocytopenia[J]. Pathology, 2021,53(2):247-256. [66] Rittener-Ruff L,Marchetti M,Matthey-Guirao E,et al.Combinations of rapid immunoassays for a speedy diagnosis of heparin-induced thrombocytopenia[J]. J Thromb Haemost,2022,20(10):2407-2418. [67] Dahiya S,Kotwal J,Langer S,et al.Real-world performance of the STic expert HIT kit and the diagnostic dilemma of borderline results in heparin induced thrombocytopenia[J]. Int J Lab Hematology, 2026,48(5):1165-1172. [68] Vayne C,Guéry E,Charuel N,et al.Evaluation of functional assays for the diagnosis of heparin induced thrombocytopenia using 5B9,a monoclonal IgG that mimics human antibodies[J]. J Thromb Haemost,2020, 18(4):968-975. [69] Warkentin T E,Arnold D M,Kelton J G,et al.Platelet-activating antibodies are detectable at the earliest onset of heparin-induced thrombocytopenia,with implications for the operating characteristics of the serotonin-release assay[J]. Chest,2018,153(6):1396-1404. [70] Warkentin T E,Nazy I,Sheppard J I,et al.Serotonin-release assay-negative heparin-induced thrombocytopenia[J]. American J Hematol,2020,95(1):38-47. [71] Barouqa M,Matta M,Reyes-Gil M.Performance evaluation of heparin-induced platelet aggregation vs serotonin release assay[J]. Am J Clin Pathol,2024, 161(2):122-129. [72] Brodard J,Alberio L,Angelillo-Scherrer A,et al.Accuracy of heparin-induced platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia[J]. Thromb Res,2020,185:27-30. [73] Meier R T,Jolink A T,Kempe M,et al.PF4-dependent P-selectin expression assay in comparison to the heparin-induced platelet activation assay for the diagnosis of heparin-induced thrombocytopenia[J]. Transfusion,2025, 65(5):848-850. [74] Wang H P,Lv P J,Qu C X,et al.Application of thrombosis-related biomarkers in the diagnosis and thrombosis risk stratification of heparin-induced thrombocytopenia patients[J]. Clin Biochem,2026,142: 111095. [75] Minei V,Valesella P,Papandrea M,et al.Combination of 2 quantitative immunoassays and clinical score algorithm to reduce false-negative results in heparin-induced thrombocytopenia: prevalence study of mauriziano hospital in Turin,Italy[J]. J Appl Lab Med,2024,9(5): 940-951. [76] Cartwright B,Mundell N.Anticoagulation for cardiopulmonary bypass,Part 2: alternatives and pathological states[J]. BJA Educ,2023,23(7):256-263. [77] 闫姝洁,李景文,杨静,等. 比伐卢定用于肝素诱导血小板减少症的体外循环心脏手术患者1例报告[J]. 中国体外循环杂志,2022,20(1):35-37. [78] 杨滢霖,王彦改,张青霞. 1例肝素诱导血小板减少症患者血浆吸附期间抗凝治疗的病例分析[J]. 实用药物与临床, 2025,28(10):779-783. [79] 唐筱婉赵会新,宋希涛,等. 低分子肝素致重度Ⅱ型血小板减少症并发血栓患者的药学监护[J]. 中国临床药理学杂志,2025,41(17):2516-2520. [80] Seiler J A,Durrani A K,Ahmeti M.A case of argatroban refractory heparin induced thrombocytopenia and thrombosis[J]. Am Surg,2023,89(8):3574-3575. [81] Porres-Aguilar M,Najera C,Mares A C,et al.Successful treatment with the oral factor xa inhibitor edoxaban in heparin-induced thrombocytopenia with thrombosis[J]. Angiology,2025,76(5):453-457. [82] Le K J,Yan Y D,Liu Y X,et al.Rivaroxaban treatment for cancer-associated venous thromboembolism in a patient with heparin-induced thrombocytopenia: a case report[J]. Transl Cancer Res,2019,8(6):2481-2484. [83] Graser A,Bauters A,Auffray J L,et al.Effectiveness and safety of therapeutic plasma exchange to modify the functionality of heparin-induced thrombocytopenia antibodies and correct profound thrombocytopenia: A case report and literature review[J]. J Intensive Med, 2023,3(4):373-375. [84] Makita N,Ohara T,Tsuji Y,et al.Early high-dose intravenous immunoglobulin for refractory heparin-induced thrombocytopenia with stroke: Two case reports[J]. J Stroke Cerebrovascular Dis,2023,32(4):107032. [85] Renna S A,Zhao X F,Kunapuli S P,et al.Novel strategy to combat the procoagulant phenotype in heparin-induced thrombocytopenia using 12-LOX inhibition[J]. Arterioscler Thromb Vasc Biol,2023,43(10):1808-1817. [86] Müller L,Dabbiru V A S,Schönborn L,et al. Therapeutic strategies in FcγIIA receptor-dependent thrombosis and thromboinflammation as seen in heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT)[J]. Expert Opin Pharmacother,2024,25(3):281-294. [87] Michael J V,Khandelwal S,Tawk A,et al.Heparin-induced thrombocytopenia immune complexes activate the inflammasome pathway in a complement-dependent manner[J]. J Thromb Haemost,2026,24(6):2130-2141. [88] Rauova L,Bdeir K,Rux A H,et al.Destabilization of PF4-antigenic complexes in heparin-induced thrombocytopenia[J]. Blood,2025,145(25):3030-3040. [89] 江冼芮,吕佳颐. 临床药师参与血液透析患者抗体阴性Ⅱ型肝素相关性血小板减少症的药学监护实践[J]. 药学实践与服务,2026,44(9):486-490. [90] Marchetti M,Barelli S,Gleich T,et al.Managing argatroban in heparin-induced thrombocytopenia: A retrospective analysis of 729 treatment days in 32 patients with confirmed heparin-induced thrombocytopenia[J]. Br J Haematol,2022,197(6):766-790. [91] Nilius H,Sinitsa E,Studt J D,et al.Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort[J]. Blood Adv,2025, 9(21):5546-5555. [92] Alfehaid L,Al Sulaiman K,Alshehri A M,et al.Fondaparinux versus argatroban for the management of suspected or confirmed heparin-induced thrombocytopenia: a propensity score-matched cohort study[J]. Front Med, 2026,13:1794887. [93] Robson R,White H,Aylward P,et al.Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function,dose,and gender[J]. Clin Pharma And Therapeutics,2002,71(6):433-439. [94] Tsu L V,Dager W E.Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia[J]. Ann Pharmacother,2011,45(10):1185-1192. [95] Gosselin R C,Dager W E,King J H,et al.Effect of direct thrombin inhibitors,bivalirudin,lepirudin,and argatroban,on prothrombin time and INR values[J]. Am J Clin Pathol,2004,121(4):593-599. [96] Donat F,Duret J P,Santoni A,et al.The pharmacokinetics of fondaparinux sodium in healthy volunteers[J]. Clin Pharmacokinet,2002,41(2):1-9. [97] Johnson P N,Benefield E C,Bui P N,et al.Fondaparinux monitoring: need for a local fondaparinux-calibrated anti-F actor xa assay[J]. J Pediatr Pharmacol Ther,2013, 18(4):318-319. [98] Mismetti P,Samama C M,Rosencher N,et al.Venous thromboembolism prevention with fondaparinux 1.5 Mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study[J]. Thromb Haemost,2012,107(6):1151-1160. [99] Bhatt V R,Aryal M R,Shrestha R,et al.Fondaparinux-associated heparin-induced thrombocytopenia[J]. European J Haematology,2013,91(5):437-441. [100] de Pont A J,Hofstra J H,Pik D R,et al. Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study[J]. Crit Care,2007,11(5):R102. [101] Magnani H N.Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)[J]. Thromb Haemost,1993,70(4):554-561. [102] Kubitza D,Becka M,Voith B,et al.Safety, pharmacodynamics,and pharmacokinetics of single doses of BAY 59-7939,an oral,direct factor Xa inhibitor[J]. Clin Pharmacol Ther,2005,78(4):412-421. [103] Stangier J,Rathgen K,Stähle H,et al.Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate[J]. Clin Pharmacokinet,2010,49(4):259-268. [104] Weinz C,Schwarz T,Kubitza D,et al.Metabolism and excretion of rivaroxaban,an oral,direct factor Xa inhibitor, in rats,dogs,and humans[J]. Drug Metab Dispos, 2009,37(5):1056-1064. [105] Samama M M,Contant G,Spiro T E,et al.Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls[J]. Thromb Haemost, 2012,107(2):379-387. [106] Stangier J,Feuring M.Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran[J]. Blood Coagul Fibrinolysis, 2012,23(2):138-143. [107] 王国强,岳品利,朱国艳,等. 心脏外科术后发生肝素诱导血小板减少症患者的临床特征分析及诊断指标评估[J]. 四川大学学报(医学版),2026,57(2):367-375. [108] 孔晓琳,刘冠男,高丽霓,等. PCI术后肝素诱导性血小板减少症研究进展[J]. 临床急诊杂志,2020,21(3):256-260. [109] 王燕姣,王翠平,李雪莉. PCI术后出现肝素诱导的血小板减少症两例[J]. 新医学,2020,51(11):881-883. [110] 高丽霓,孔晓琳,刘冠男,等. PCI术后肝素诱导的血小板减少症Ⅰ型与Ⅱ型的中医证候特征及证候差异性研究[J]. 现代中西医结合杂志,2020,29(13):1383-1386. [111] Gameiro J,Jorge S,Lopes J A.Haemodialysis-related-heparin-induced thrombocytopenia: Case series and literature review[J]. Nefrologia,2018,38(5):551-557. [112] 张圣雨,宋惠珠,张秀红,等. 血液透析患者以普通肝素抗凝致血小板减少的药学监护[J]. 医药导报,2018,37(4): 489-492. [113] 甘淑燕,柳美秀,黄赛虎,等. 危重症儿童体外膜肺氧合期间并发肝素诱导的血小板减少症临床分析[J]. 中国小儿急救医学,2022,29(11):863-867. [114] 徐春苗. 肝素诱导的血小板减少症(HIT)抗体在妊娠期患者HIT中的临床诊断效能[J]. 临床医学研究与实践, 2021,6(36):113-114. [115] 储赞军,马睿,任静,等. 肝素诱导的血小板减少症抗体检测在妊娠期患者中的诊断效能评价[J]. 临床检验杂志, 2020,38(5):333-337. |
| [1] | 李翠莹. 胎儿新生儿溶血病的诊疗策略探讨*[J]. 临床输血与检验, 2021, 23(1): 24-28. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
